DOCSLIB.ORG

LUDWIG LINK | AUGUST 2020 the Cover Incorporates Aslice of Cover the Incorporates Result

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LUDWIG LINK | AUGUST 2020 the Cover Incorporates Aslice of Cover the Incorporates Result LUDWIG LINK | AUGUST 2020 IN THIS ISSUE LUDWIG 7 | Remembering 21 | Ask a Sam Gambhir scientist LINK Renowned scientist, A special section Ludwig Professor, mentor on COVID-19 and AUGUST 2020 and inventor dies at 57 cancer research LIFE-CHANGING SCIENCE 1 ON THE COVER The cover image of this issue derives from a Zoom “whiteboard” generated during a townhall meeting of the Ludwig New York office. Attendees were asked to paint the word or phrase each associates with the genuine achievement of diversity and inclusiveness. The activity was inspired by discussions following the death of George Floyd, which has provoked sustained protests against systemic racism in the U.S. and a broader social awakening to prejudice in its many forms. The cover incorporates a slice of the result. LUDWIG LINK | AUGUST 2020 2 LUDWIG LINK ludwigcancerresearch.org AUGUST 2020 LETTER TABLE OF CONTENTS Cancer isn’t waiting for COVID-19 to go away. Nor are Ludwig scientists. Awards and distinctions 4 For high-impact research 4 Though lockdowns imposed by For general scientific excellence 4 the pandemic have disrupted lab For linking science to human benefit 5 operations, Ludwig researchers For illuminating the dark genome 6 have been hard at work, analyzing For a stellar start 6 data, preparing papers and planning new experiments. You’ll In memoriam 7 find here a brief report on the Ludwig Scientific Insights Sanjiv Sam Gambhir 7 webinars this past quarter, which shared tips and resources Navigating the pandemic 8 on managing through the pandemic. Managing the new normal 8 The research news in this issue includes a brief on a clinical People on the move 9 trial launched by Ludwig Johns Hopkins researchers to A new scientific advisor 9 evaluate a generic blood pressure drug as a preventive News roundup 9 intervention for the deadliest consequence of COVID-19, the Diverse landscapes 9 cytokine storm. Our other features include items on, among Toward early detection 10 other things, a urine test to detect lung cancer and a new An ounce of prevention 11 CAR-T cell that can be switched on and off on demand. A nip in the bud 12 A CAR-T full of promise 12 LUDWIG LINK | AUGUST 2020 We also have some sad news in this issue: Ludwig Professor Very smart toilet 13 at Stanford Sanjiv Sam Gambhir died in July from a cancer Helpful bugs 13 Secondhand sensitivity 14 of unknown origin. A physician-scientist and an inspired Early warning system 14 inventor, Sam was also a beloved colleague, teacher and A long read 15 mentor to many. He will be missed. Bugs sting cancer 15 Traitorous targets 16 Along the usual honors and awards won by Ludwig Innate potential 16 researchers, you’ll learn a little in this issue about the Calculated odds 17 accomplished immunologist Bob Schreiber—a new member Foci for research 17 of the Ludwig Institute’s Scientific Advisory Committee. Kill switch 18 We also thought we’d ask Ludwig scientists to share their Telltale number 18 thoughts on how the pandemic is likely to influence their own An environment of resistance 19 work and cancer research and care in general. Find out what CRISPR replicas 19 Ventilatory warning 20 they said in our special Ask a scientist section. Ask a scientist 21 Happy reading! A special section on COVID-19 and cancer research 21 Rachel Reinhardt Required reading 35 Senior Vice President for Communications 3 Awards and distinctions FOR HIGH-IMPACT RESEARCH Five Ludwig scientists were named Fellows of the Academy of the American Association for Cancer Research (AACR) Class of 2020 in May. The honorees include Ludwig Oxford’s Sir Peter Ratcliffe—who was recognized for his landmark discoveries on how cells sense Peter Ratcliffe Rakesh Jain oxygen and respond to its depletion—and Ludwig Oxford Ludwig Harvard four Ludwig Harvard researchers. Rakesh Jain was recognized for his investigations of how the tumor microenvironment fuels tumor progression and confers resistance, and how anti-angiogenic therapy can normalize tumor blood vessels and improve chemo- and immunotherapies; Kornelia Polyak for dissecting the role of intratumoral heterogeneity in breast cancer and cancer metastasis; Alan D’Andrea for LUDWIG LINK | AUGUST 2020 his contributions to the field of DNA Kornelia Polyak Alan D’Andrea damage and repair, and for defining how Ludwig Harvard Ludwig Harvard such defects drive Fanconi anemia; and Myles Brown for his discoveries on the role steroid hormones and their cellular receptors play in the initiation and progression of various cancers. Election to the Academy is an honor bestowed by the AACR on those whose scientific contributions have “propelled significant innovation and progress against cancer.” Myles Brown Ludwig Harvard 4 Awards and distinctions FOR GENERAL FOR LINKING SCIENCE SCIENTIFIC EXCELLENCE TO HUMAN BENEFIT In April, Ludwig Oxford Director Xin Lu Ludwig Harvard Co-director George was elected to the Fellowship of the Demetri was named the recipient of the Royal Society. Xin was recognized by the 2020 David A. Karnofsky Award in April. Royal Society for her contributions to He will deliver the Karnofsky Lecture at our understanding of cancer cell biology, the virtual ASCO meeting in August 2020. particularly her work on the regulation Among the most prestigious honors of p53, a tumor suppressor protein bestowed by the American Society of whose inactivation or mutation aids the Xin Lu Clinical Oncology, the Karnofsky Award progression of a wide variety of cancers. Ludwig Oxford recognizes outstanding contributions She is perhaps best known for leading the to cancer research, diagnosis and discovery and functional characterization treatment. George has made major of the ASPP family of proteins, which contributions to our understanding and control p53 activity. Aside from opening treatment of cancers that arise in the new approaches to selectively killing soft tissue and bone, known as sarcomas. cancer cells, Xin’s continuing exploration His development of selective inhibitors of those proteins has exposed their role of the mutated KIT oncogene led in 2002 in other disorders, including sudden to historic approval of the first targeted cardiac death and brain abnormalities. therapy, imatinib, for gastrointestinal Xin has directed Ludwig’s Oxford Branch stromal tumors (GISTs), the most common LUDWIG LINK | AUGUST 2020 since it was established in 2007 and is sarcoma. Imatinib was initially developed a Professor in the Nuffield Department to inhibit the fusion oncoprotein, BCR- of Medicine at the University of Oxford, George Demetri ABL, in chronic myeloid leukemia; GIST a Fellow of the Academy of Medical Ludwig Harvard was the second approval. With George’s Sciences and the Royal Society of Biology, collaboration, the drug has also been a Fellow by election of the Royal College approved for DFSP, a different sarcoma of Pathologists and a member of the driven by a PDGF-gene fusion and other European Molecular Biology Organization. blood cancers. George’s subsequent Founded in 1660, the Royal Society is a research led to the approval of second storied fellowship of eminent scientists, and third generation treatments for GISTs, engineers and technologists in the UK as well as treatments for other sarcomas. and the Commonwealth whose mission His work has influenced the development is to “recognize, promote, and support of drugs for a wide range of malignancies, excellence in science and to encourage including the recent inhibitors of the development and use of science for oncogenic TRK-fusions in rare subsets of the benefit of humanity.” virtually all cancers. 5 Awards and distinctions FOR ILLUMINATING THE DARK GENOME Ludwig Stanford Professor Howard Chang positional identity—work that led to his was elected to the National Academy lab’s discovery of a sprawling family of of Sciences (NAS) and the American genes encoding long noncoding RNAs Academy of Arts and Sciences (AAAS) that regulate gene activity and play in April. Howard’s lab has developed critical roles in an array of biological powerful new technologies to explore processes, including cancer. Established how the large expanses of the genome in 1780, the AAAS honors excellence and that encode no proteins—98% of seeks “to cultivate every art and science Howard Chang the whole—control the expression which may tend to advance the interest, Ludwig Stanford of the remaining 2%. Applying these honor, dignity, and happiness of a free, technologies, Howard and his colleagues independent, and virtuous people.” The have made transformative discoveries on NAS was established in 1863 and charged how regulatory DNA sequences in these with providing independent, objective regions influence biological phenomena advice to the nation on matters related ranging from embryonic development to science and technology. Election to to aging to the genesis of cancers. the NAS is considered one of the highest Howard has also explored how cells of honors a scientist can receive. the body establish and maintain their LUDWIG LINK | AUGUST 2020 FOR A STELLAR START In May, Ludwig Johns Hopkins researcher odds for a cure. Jonathan also received Jonathan Dudley was named a winner this year’s Benjamin Castleman Award of this year’s prestigious Damon Runyon from the United States and Canadian Physician-Scientist Training Award for Academy of Pathology at its national his work on a new approach to screening conference. The award is given to one for bladder, endometrial and ovarian pathologist under forty each year for an cancers. A board-certified pathologist, outstanding paper in the field of human Jonathan is developing a way to detect pathology. Jonathan was recognized for Jonathan Dudley cells in urine and pap smears that have work he initiated during his residency Ludwig Johns Hopkins abnormal amounts of DNA, or aneuploidy. and fellowship with Ludwig Stanford Aneuploidy is present in over 90% of investigators Maximilian Diehn and Ash cancers, but is difficult to detect with Alizadeh creating a method to detect traditional liquid biopsy methods in the bladder cancer from cell-free DNA in urine early stages of tumor growth.
Load more

Recommended publications
  • Ludwig Institute Consolidated Financial Report for 2012
    Ludwig Institute for Cancer Research Ltd Statutory Financial Statements 2012 Ludwig Institute for Cancer Research Ltd, Zurich Report of the Statutory Auditor on the Financial Statements to the General Meeting of Shareholders Financial Statements 2012 KPMG AG Zurich, May 14, 2013 - 8 - Ludwig Institute for Cancer Research Ltd - 9 - Ludwig Institute for Cancer Research Ltd - 10 - Ludwig Institute for Cancer Research Ltd Balance Sheet as at December 31, 2012 USD CHF 2012 2011 2012 2011 Assets Current assets Liquid funds (Notes 1 & 2) 22,138,495 15,385,587 20,265,932 14,387,043 Fixed term deposits (Notes 1 & 2) 6,439,223 14,765,382 5,894,618 13,806,828 Other receivables - Third parties 2,640,414 3,461,456 2,417,059 3,236,845 External funding 3,888,612 3,411,279 3,559,672 3,189,902 Prepayments and accrued income 3,120,349 2,681,977 2,856,387 2,507,918 Total current assets 38,227,093 39,705,681 34,993,668 37,128,536 Fixed assets Financial fixed assets - Investments (Note 4) 7,080,599 5,103,000 6,481,635 4,771,815 Other (Notes 1 & 5) 1,517,679 1,987,090 1,389,319 1,858,180 Total fixed assets 8,598,278 7,090,090 7,870,954 6,629,995 Total assets 46,825,371 46,795,771 42,864,622 43,758,531 Liabilities and Net worth Current liabilities Accounts payable - third parties (Note 7) 8,873,562 10,624,684 8,122,981 9,935,143 Accruals (Note 1) 6,507,197 7,514,082 5,956,785 7,026,474 Provisions (Notes 1 & 8) 5,839,674 5,860,811 5,345,653 5,480,518 Deferred income (Notes 1 & 10) 6,887,424 10,096,102 6,304,919 9,441,140 Total current liabilities 28,107,857 34,095,679
    [Show full text]
  • Ludwig Institute Consolidated Financial Report for 2019
    Ludwig Institute for Cancer Research Ltd, Zurich Report of the Statutory Auditor on the Consolidated Financial Statements to the General Meeting of Shareholders Consolidated Financial Statements 2019 KPMG AG Zurich, May 22, 2020 KPMG AG Audit Räffelstrasse 28 PO Box Telephone +41 58 249 31 31 CH-8045 Zurich CH-8036 Zurich Internet www.kpmg.ch Report of the Statutory Auditor to the General Meeting of Shareholders of Ludwig Institute for Cancer Research Ltd, Zurich Report of the Statutory Auditor on the Consolidated Financial Statements As statutory auditor, we have audited the accompanying consolidated financial statements of Ludwig Institute for Cancer Research Ltd, which comprise the balance sheet, income statement, statement of cash flows, statement of capital changes and notes for the year ended December 31, 2019. Board of Directors’ Responsibility The board of directors is responsible for the preparation of the consolidated financial statements in accordance with Swiss GAAP FER and the requirements of Swiss law. This responsibility includes designing, implementing and maintaining an internal control system relevant to the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error. The board of directors is further responsible for selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances. Auditor’s Responsibility Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with Swiss law and Swiss Auditing Standards. Those standards require that we plan and perform the audit to obtain reasonable assurance whether the consolidated financial statements are free from material misstatement.
    [Show full text]
  • Don Cleveland Shows How Research in Neuroscience Is Leading to New Approaches to Treat Brain Cancer
    18 INTERDISCIPLINARY RESEARCH Ludwig Cancer Research has a long tradition of nurturing investigators who see connections among different fi elds. The work of Ludwig scientist Don Cleveland shows how research in neuroscience is leading to new approaches to treat brain cancer. 19 TECHNIQUE TO VANQUISH DISEASE IN NERVOUS SYSTEM APPLIED TO CANCER Richard Smith, a neurologist who has a roster of patients with neurodegenerative disease, would not leave Ludwig scientist Don Cleveland alone. Cleveland’s laboratory at Ludwig San Diego had the means to test an idea to help people with Don Cleveland amyotrophic lateral sclerosis (ALS, also called Lou Gehrig’s disease), whom Smith saw regularly at his San Diego clinic. “He was relentless in badgering me,” recalls Cleveland of their interactions in 2005. The idea was to silence a gene that is mutated in a proportion of inherited ALS cases, caused by mutation in SOD-1 (superoxide dismutase 1), in the hope that quelling the bad gene could also quell disease. To silence the gene, Smith suggested using an antisense oligonucleotide, a small piece of single-stranded DNA. It was designed to destroy the gene’s mRNA, a molecular intermediary between the gene and the protein it encodes. Smith proposed testing the oligonucleotide in animals with a pump that would infuse the DNA drug directly into the cerebrospinal fl uid, essentially bathing the brain and spinal cord in it. To work, the drug needed to be taken up by the motor neurons. Cleveland didn’t think this would happen. But Smith, who later spent two years in Cleveland’s lab working on the project, argued that they had nothing to lose.
    [Show full text]
  • LUDWIG LINK | NOVEMBER 2013 Irector of Communications Irector Steinhardt Achel Positive
    LUDWIG LINK NOVEMBER 2013 IN THIS ISSUE 3 | Oxford Report 11 | Irv Weissman Q&A News from the Ludwig A conversation with the scientific retreat Ludwig Stanford director Continued inside > LUDWIG LINK | NOVEMBER 2013 1 LUDWIG LINK NOVEMBER 2013 LETTER Fall is an ideal time to refresh the mind and engage in creative new thinking and direction. TABLE OF CONTENTS And last month started off on a high note, with a Ludwig retreat Meeting Notes 3 in Oxford that packed three Getting to know you days with information sharing 3 Abracadabra and networking. The caliber 4 of the content, speakers and attendees was amazing Company News in itself. It was an unparalleled opportunity to foster 4 interactions and collaborations among some of the most Well designed 4 distinguished researchers from around the world. News Roundup 5 The passion was palpable from the presentations to the Buyer beware 5 coffee breaks and after-hour conversations. Off-site Dark horse 5 meetings encourage out-of-the-box thinking because Don’t delete 6 being in unfamiliar surroundings can break old habits Sn(i)ps 7 and generate energy, leading to fresh ideas and deeper Fickle finger of cell fate 7 LUDWIG LINK | NOVEMBER 2013 thinking. The splice of life 8 Eats, shoots and leaves 9 And the feedback couldn’t have been more positive. “The retreat offered me an incredible opportunity to Ask a Scientist 10 foster new and deeper collaborations with other Ludwig labs. It felt like the cancer biologist’s version of AC/DC’s Q&A with Irv Weissman 11 greatest hits album!” said Adriel Cha of Ludwig Stanford.
    [Show full text]
  • LUDWIG LINK | JULY 2014 Director of Communications Director Steinhardt Rachel Sincerely, Reading! Happy More Prizes
    LUDWIG LINK 2014 | JULY IN THIS ISSUE LUDWIG 8 | News Roundup 14 | Q&A Bird virus boosts Peter Gibbs of Ludwig LINK effectiveness of Melbourne-WEHI on immunotherapy effort inspiration and science JULY 2014 Continued inside > 1 LUDWIG LINK JULY 2014 LETTER Antoine-Augustin Parmentier got one in 1773 for identifying a vegetable that could ease TABLE OF CONTENTS famines, and popularized the potato in France. About a Awards and distinctions 3 century and a half later, Charles Cancer’s worst enemy 3 Lindbergh got one for flying Turbocharged team 3 from New York to Paris, and Inspired immunotherapist 4 revolutionized the business of aviation. More recently, A new chief 4 the X Prize Foundation used one to kick off a commercial Nonpareil class 5 space race. Meeting notes 6 A prize is what each of them got. Prizes inspire human achievement at least as much as they celebrate it. And Omne trium perfectum 6 they give the rest of us an opportunity to tip our collective hats to the intrepid, the inspired and the awe-inspiring. News roundup 7 Real hope for real change 7 In this issue you’ll read about 13 Ludwig scientists who Of birds and men 8 dared to ask big questions. Each of the awards won by our Developmental disorders 8 LUDWIG LINK 2014 | JULY researchers this year recognizes significant contributions Clairvoyant 9 to cancer research or therapy. Taken together, they serve Making headway 10 as testament to the high caliber of Ludwig research and DNA detectives 10 the dedication of its scientists. Break repair 11 The nuclear option 12 We also asked three young Ludwig researchers from around the world how prizes impact science.
    [Show full text]
  • 2018 Progress Report and 2019 Update
    2018 Progress Report and 2019 Update Defeat GBM Research Collaborative Key Personnel: PRINCIPAL INVESTIGATORS • Tim Cloughesy, MD A NOTE FROM THE CEO University of California, Los Angeles • John de Groot, MD MD Anderson Cancer Center Over the past five years, the Defeat GBM Research Collaborative has stood as a testament to the power of ideas, collaboration, and the philanthropic partnership • Frank Furnari, PhD between patient advocacy nonprofits like NBTS and a dedicated community of Ludwig Cancer Research, supporters. University of California, San Diego • Dimpy Koul, PhD When we launched Defeat GBM as our flagship research initiative in 2014, we MD Anderson Cancer Center sought to do something different. Decades of grant-making in the traditional form of funding separate, individual research projects (one- to two-year grants • Ingo Mellinghoff, MD to a single Principle Investigator) had produced extraordinary knowledge of the Memorial Sloan Kettering Cancer Center biology of glioblastoma cells, but not nearly enough of this work was primed to • Paul Mischel, MD move out of research laboratories and into clinical trials for patients. Ludwig Cancer Research, University of California, San Diego NBTS wanted to see what could be accomplished if, instead of continuing this traditional model of research funding, we deep-funded a team of expert • Erik Sulman, MD, PhD researchers, over a five-year period, to work collaboratively. This team would be NYU Langone’s Perlmutter charged with working across the continuum of research to translate a scientific Cancer Center discovery into an actionable treatment strategy and/or medical product that could • Roel Verhaak, PhD be tested in clinical trials, and hopefully become an approved new therapeutic The Jackson Laboratory option for patients.
    [Show full text]
  • 2019 Research Highlights
    2019 RESEARCH HIGHLIGHTS LIFE-CHANGING SCIENCE 1 2 WELCOME Welcome to the Ludwig 2019 Research Highlights Report. As we do every year, we’ve selected a handful of recent discoveries and advances made by Edward A. researchers affiliated with Ludwig Cancer Research and woven the stories behind each into McDermott Jr. President and profiles of the scientists responsible for them. Chief Executive Officer The intention is to illustrate the depth and breadth of Ludwig’s life-changing science. But the stories told in this report also speak to the human side of science—the aspirations and fascinations that drive scientific research, the relationships that fuel its progress—as much as the fundamental challenges of cancer biology and care. Beyond that, they illustrate the truly global scope of the scientific effort to defeat cancer. You will thus read here about the improbable journey of a boy living hand-to-mouth in a coastal Chi Van Dang Chinese village to a U.S. university and on to the frontiers of medical nanotechnology, where Scientific his inventions, now in clinical trials, are putting a new twist on chemo- and radiotherapy. Director You’ll learn about how a bright young girl from California moved to aid children with Down syndrome grew into an inspired clinical neurologist whose research is bringing new hope to kids diagnosed with an intractable brain cancer and people afflicted by the cognitive decline caused by chemotherapy. Another profile charts the path taken by a British nephrologist to a landmark discovery of how cells sense and respond to oxygen—a system of profound significance in cancer—and his recent identification of a second, evolutionarily ancient cellular oxygen sensor.
    [Show full text]
  • Ludwig Presence at 2016 AACR Annual Meeting
    Ludwig Presence at 2016 AACR Annual Meeting Ludwig Scientist (s) Affiliation (s) Session Time Location Session Type Session Title Presentation/Abstract Title & Time SATURDAY, APRIL 16 Using Tumor Biology to Drive Room 288, Morial Convention 9:30am - 9:55am: Immunotherapies for Sarcoma: Crystal Mackall Ludwig Stanford 8:00am - 10:00am Educational Session More Effective Sarcoma Center Progress and Challenges Therapy Room 278, Morial Convention Cancer Immunology for the Crystal Mackall Ludwig Stanford 10:15am -12:15pm Educational Session 10:15am - 12:15pm: Education Manuscript Center Non-Immunologist: Tutorial SUNDAY, APRIL 17 Ovarian cancer Room 343, Morial Convention Meet-the-Expert George Coukos Ludwig Lausanne 7:00am - 8:00am immunotherapy. From bench Invited speaker Center Session to bedside Cellular Plasticity, Cellular Room 288, Morial Convention Meet-the-Expert Xin Lu Ludwig Oxford 7:00am - 8:00am Heterogeneity and Single Cell Invited speaker Center Session Sequencing Stapled Peptides as a New Room 357, Morial Convention Meet-the-Expert Form of Medicine for David Lane Ludwig New York 7:00am - 8:00am Invited speaker Center Session Oncology Targets: Challenges and Progress Room 271, Morial Convention Meet-the-Expert The Role of Metabolism in Matthew Vander Heiden Ludwig MIT 7:00am - 8:00am Invited speaker Center Session Supporting Tumor Growth Thirteenth Annual AACR Award for Lifetime Bob Weinberg Ludwig MIT 8:15am - 9:00am Hall F, Morial Convention Center Awards and Lectures Award recipient Achievement in Cancer Research Thirty-Sixth
    [Show full text]
  • Consummate Neuro-Oncologist
    THE CONSUMMATE NEURO-ONCOLOGIST Michelle Monje’s teenage project to aid the disabled led her to neurology and a research career that’s bringing new hope for the treatment of childhood brain cancers and the mind-fog caused by chemotherapy. Competitive figure skating was once a big abiding interest in neurology. In keeping part of Michelle Monje’s life. By the time she with her mother’s advice, Monje has over was in middle school in the Bay Area of San the past quarter century made significant Francisco, Monje was squeezing in as many contributions to our understanding of as 35 hours of practice every week at the the brain’s postnatal plasticity and the rink. Then her mother, who’d started at IBM in neurological disorders caused by cancer the late 60’s as a computer programmer and therapies. She has also led the charge worked her way up to the executive ranks, against a swiftly lethal childhood cancer of had a little chat with her. “She pointed out the brainstem known as diffuse intrinsic that dedicating that much time to a sport pontine glioma (DIPG), charting new was great,” Monje recalls, “but perhaps I approaches to the treatment of the long- should also think about how I’m going to be neglected cancer and other high-grade productive and contribute to the rest of the gliomas that she is now—or soon will be— world.” Just 13 at the time, Monje mulled evaluating in clinical trials. the matter for a spell and came up with a precociously fitting answer: She created In 2018, Monje and her colleagues reported a figure skating program for children with in Cell their dissection of the cellular Down syndrome.
    [Show full text]
  • Web Cavenee, Who Study the Diverse Cellular Mechanisms That Drive Cancer
    24 COMBINATION Ludwig Cancer Research has long fostered research in several core areas. These include the study of melanoma, brain tumors and, more broadly, immunotherapy— research on how to modulate the immune system to attack tumors. Ludwig’s emphasis on these core areas has led to a multipronged view of tumors, fostering the development of therapies that can be used in combination. This approach may counteract cancer more effectively than any single treatment used in isolation. 25 TAPPING INTO NEW TARGETS FOR BRAIN CANCER If any tumor type is a candidate for combination therapy, it is glioblastoma multiforme. This aggressive brain cancer defi es most treatment strategies. Chemotherapy barely touches it, and drugs that target cancer-causing cellular molecules are also remarkably ineffective in treating it. Median survival is 15 months after diagnosis. Ludwig has long supported research programs to tackle this disease. Recently, physician-scientist Paul Mischel, a former faculty member at the University of California, Los Angeles, was recruited to the Ludwig San Diego team. He Paul Mischel has helped design and lead molecular analysis in fi ve clinical trials of therapies targeting cancer-related cellular molecules. Mischel’s expertise complements a team with strengths in basic research. It includes geneticist Frank Furnari and Ludwig San Diego director Web Cavenee, who study the diverse cellular mechanisms that drive cancer. Mischel’s move to Ludwig last fall was a natural evolution of an ongoing long- distance interaction with Furnari and Cavenee. “We have shared interests and complementary approaches,” says Mischel. “The synergies among us were Frank Furnari so great that it made sense to work closer together.” One of the trio’s most recent projects delved into why two drugs designed to inhibit a cellular molecule called epidermal growth factor receptor (EGFR) work poorly in patients with glioblastoma.
    [Show full text]
  • Benoît Ludwig Brussels Van Den Eynde
    VAN DEN EYNDE BENOÎT BRUSSELS LUDWIG Photo by Flynn Larsen 24 THE TUMOR DEFENSE DISMANTLER He began his career helping to lay the scientific groundwork for modern immunotherapy. Now he’s unraveling the myriad ways tumors thwart immune attack—and showing how to undo those defenses. In science, as in many other things, it’s the researchers expected the antigen would surprises that tend to stick with you—and be a randomly mutated version of a normal sometimes in more ways than one. gene—a neoantigen—which would appear foreign to T cells, provoking attack. “To Benoît Van den Eynde got a big one nearly our surprise, the antigen turned out to be three decades ago, while working with identical to the normal gene,” recalls Ludwig Thierry Boon, the founding director of the Member Van den Eynde. “We called it P1A Brussels Branch of the Ludwig Institute and realized quite quickly that the gene is for Cancer Research. Boon had previously expressed in the tumor but mostly silent shown in a series of milestone studies in the in normal tissues.” Reported in 1991, it was late 70s and early 80s that the mammalian the first of what would come to be called immune system can detect and clear cancer, the “MAGE-type” or “cancer testis” antigens, a possibility most scientists doubted at the which are expressed in human cancers as time. By the mid-80s, his team was racing to well and would become central to several find in mice and humans the first example immunotherapy strategies. of a naturally occurring cancer antigen, a molecular flag that marks diseased cells for P1A, for its part, stuck around as a useful targeting by T cells of the immune system.
    [Show full text]
  • Cancer Hunter
    THE CANCER HUNTER Nickolas Papadopoulos’ early fascination with molecular genetics fueled a career-long adventure mapping cancer genomes, unearthing cancer genes and devising tests for the minimally invasive detection of cancer. Nickolas Papadopoulos was about as gathered a few people in a little room outside surprised as he was relieved to hear the his office that we called the kitchen—a voice on the other end of the line when he refrigerator, small tables and a whiteboard,” answered his lab phone one afternoon in the Papadopoulos recalls. “He said, ‘OK, now summer of 1992. The voice belonged to Bert you’re going to present your work to us.’ ” Vogelstein, a man he had never met before Vogelstein brushed off his protests, saying and to whom he had sent his one and only it wouldn’t be a problem if he knew his application for a postdoctoral position. If he stuff. After the presentation and a little didn’t get it, Papadopoulos was ready to fly Q&A, he had someone show Papadopoulos home to his native Greece. He had labored around the lab. When he returned, he found and fussed over his letter to the up-and- Vogelstein hammering out a letter on his coming cancer geneticist, but the fact was electric typewriter. The job would start in he had no experience, let alone publications, a few months, it said; Papadopoulos had in the field. Fortunately, Vogelstein had to promise he wouldn’t even interview ignored that deficiency and was now inviting elsewhere. him over for an interview. Just come over, he said.
    [Show full text]